Abstract
Saccharomyces boulardii (S. boulardii) has beneficial effects in the treatment of intestinal inflammation; however, little is known about the mechanisms by which these effects occur. We investigated the effects of S. boulardii on the expression of peroxisome proliferator-activated receptor-gamma (PPAR-γ) and interleukin-8 (IL-8), using human HT-29 colonocytes and a rat model of trinitrobenzene sulfonic acid (TNBS)-induced colitis. The effect of S. boulardii on gene expression was assessed by semi-quantitative reverse transcription–polymerase chain reaction (RT-PCR), and Northern blot and Western blot assays. Pharmacological inhibitors for various signaling pathways were used to determine the signaling pathways implicated in the S. boulardii regulation of PPAR-γ and IL-8. We found that S. boulardii up-regulated and down-regulated PPAR-γ and IL-8 expression at the transcription level, both in vitro and in vivo (P < 0.05, respectively). Saccharomyces boulardii blocked tumor necrosis factor-alpha (TNF-α) regulation of PPAR-γ and IL-8 through disruption of TNF-α-mediated nuclear factor kappa B (NF-κB) activation. Furthermore, S. boulardii suppressed colitis and expression of pro-inflammatory cytokine genes in vivo (P < 0.05, respectively). Our study demonstrated that S. boulardii reduces colonic inflammation and regulates inflammatory gene expression.
Similar content being viewed by others
References
Podolsky DK (1991) Inflammatory bowel disease. N Engl J Med 325:928–937
Podolsky DK (1991) Inflammatory bowel disease. N Engl J Med 325:1008–1016
Hanauer SB (1996) Inflammatory bowel disease. N Engl J Med 334:841–848. doi:10.1056/NEJM199603283341307
Fuller R (1989) Probiotics in man and animals. J Appl Bacteriol 66:365–378
Goossens D, Jonkers D, Stobberingh E, van den Bogaard A, Russel M, Stockbrugger R (2003) Probiotics in gastroenterology: indications and future perspectives. Scand J Gastroenterol 239:15–23
Plein K, Hotz J (1993) Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea—a pilot study. Z Gastroenterol 31:129–134
Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000) Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 45:1462–1464. doi:10.1023/A:1005588911207
Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V et al (2000) Prokaryotic regulation of epithelial responses by inhibition of IkB-α ubiquitination. Science 289:1560–1563. doi:10.1126/science.289.5484.1560
Sougioultzis S, Simeonidis S, Bhaskar KRB, Chen X, Anton PM, Keates S et al (2006) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343:69–76. doi:10.1016/j.bbrc.2006.02.080
Schoonjans K, Staels B, Auwerx J (1996) Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37:907–925
Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 8:1224–1234. doi:10.1101/gad.8.10.1224
Strober W, Fuss IJ, Blumberg RS (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20:495–549. doi:10.1146/annurev.immunol.20.100301.064816
Di Sabatino A, Ciccocioppo R, Luinetti O, Ricevuti L, Morera R, Cifone MG et al (2003) Increased enterocyte apoptosis in inflamed areas of Crohn’s disease. Dis Colon Rectum 46:1498–1507. doi:10.1007/s10350-004-6802-z
Jones DC, Ding X, Daynes RA (2002) Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is expressed in resting murine lymphocytes. The PPAR alpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem 277:6838–6845. doi:10.1074/jbc.M106908200
Cunard R, DiCampli D, Archer DC, Stevenson JL, Ricote M, Glass CK et al (2002) WY14, 643, a PPAR α ligand, has profound effects on immune responses in vivo. J Immunol 169:6806–6812
Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB (2002) Thiazolidinedione activation of peroxisome proliferator-activated receptor γ can enhance mitochondrial potential and promote cell survival. J Biol Chem 277:31781–31788. doi:10.1074/jbc.M204279200
Natarajan C, Bright JJ (2002) Peroxisome proliferator-activated receptor-γ agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun 3:59–70. doi:10.1038/sj.gene.6363832
Gupta RA, Sarraf P, Brockman JA, Shappell SB, Raftery LA, Willson TM et al (2003) Peroxisome proliferator-activated receptor γ and transforming growth factor-β pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J Biol Chem 278:7431–7438. doi:10.1074/jbc.M208076200
Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M et al (2001) Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15:3263–3277. doi:10.1101/gad.207501
Lee SK, Kim HJ, Chi SG, Jang JY, Nam KD, Kim NH et al (2005) Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-γ in HT-29 cells. Korean J Gastroenterol 45:328–334
Chung SK, Lee MG, Ryu BK, Lee JH, Han J, Byun DS, Chae KS, Lee KY, Jang JY, Kim HJ, Chi SG (2007) Frequent alteration of XAF1 in human colorectal cancers: implication for tumor cell resistance to apoptotic stresses. Gastroenterologia 132:2459–2477. doi:10.1053/j.gastro.2007.04.024
Medina C, Videla S, Radomski A, Radomski M, Antolin M, Guarner F et al (2001) Therapeutic effect of phenantroline in two rat models of inflammatory bowel disease. Scand J Gastroenterol 36:1314–1319. doi:10.1080/003655201317097182
Craig R, Larkin A, Mingo AM, Thuerauf DJ, Andrews C, McDonough PM et al (2000) p38 MAPK and NF-kB collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 275:23814–23824. doi:10.1074/jbc.M909695199
Elson CO, Sartor RB, Tennyson GS, Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109:1344–1367. doi:10.1016/0016-5085(95)90599-5
Boismenu R, Chen Y (2000) Insights from mouse models of colitis. J Leukoc Biol 67:267–278
Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C (1996) Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 64:5225–5232
Czerucka D, Rampal P (1999) Effect of Saccharomyces boulardii on cAMP- and Ca2+ -dependent Cl- secretion in T84 cells. Dig Dis Sci 44:2359–2368. doi:10.1023/A:1026689628136
Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R et al (1997) The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 272:18779–18789. doi:10.1074/jbc.272.30.18779
Rosen ED, Spiegelman BM (2001) PPARγ : a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731–37734. doi:10.1074/jbc.M106424200
Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM (2001) PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48–52. doi:10.1038/83336
Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG et al (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA. Nat Immunol 5:104–112. doi:10.1038/ni1018
Mercurio F, Manning AM (1999) Multiple signals converging on NF-kB. Curr Opin Cell Biol 11:226–232. doi:10.1016/S0955-0674(99)80030-1
Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-kB activity. Annu Rev Immunol 18:621–663. doi:10.1146/annurev.immunol.18.1.621
Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K et al (2001) Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J Exp Med 193:827–838. doi:10.1084/jem.193.7.827
Acknowledgments
This work was supported by grants from the Korea Research Foundation (KRF-2005-003-E00084) and the Korea Science and Engineering Foundation (the biofood R&D Program).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Lee, S.K., Kim, Y.W., Chi, SG. et al. The Effect of Saccharomyces boulardii on Human Colon Cells and Inflammation in Rats with Trinitrobenzene Sulfonic Acid-Induced Colitis. Dig Dis Sci 54, 255–263 (2009). https://doi.org/10.1007/s10620-008-0357-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-008-0357-0